Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150999 | 0.96 | TRPV4 (0.41) | TRPV4ALDH1A1L3MBTL1FLT3HDAC8 | |
| SCHEMBL147014 | 0.93 | TRPV4 (0.43) | TRPV4ALDH1A1L3MBTL1FLT3HDAC8 | |
| SCHEMBL145974 | 0.87 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1FLT3HDAC8MAPT | |
| SCHEMBL150262 | 0.85 | FLT3 (0.50) | TRPV4ALDH1A1L3MBTL1FLT3MAPT | |
| SCHEMBL146472 | 0.83 | HDAC8 (0.43) | ALDH1A1L3MBTL1FLT3HDAC8MAPT | |
| SCHEMBL146202 | 0.80 | FLT3 (0.40) | ALDH1A1L3MBTL1FLT3HDAC8MAPT | |
| SCHEMBL18721778 | 0.77 | KEAP1 (0.37) | ALDH1A1FLT3GAALMNASMN1; SMN2 | |
| SCHEMBL29482639 | 0.76 | TRPV4 (0.68) | TRPV4ALDH1A1L3MBTL1GAAALPL | |
| SCHEMBL74997 | 0.76 | TRPV4 (0.68) | TRPV4ALDH1A1L3MBTL1GAAALPL | |
| SCHEMBL4493224 | 0.76 | TRPV4 (0.49) | TRPV4ALDH1A1L3MBTL1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617276-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150111962-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-8921349-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2429290-B1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2429290-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | Purdue Research Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132494-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | GHOSH ARUN K (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | CTSS, DNPEP, PEPD | TRPV4 4626/4885ALDH1A1 2465/4885L3MBTL1 1928/4885 |
| US-20150111962-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | CTSS, DNPEP, PEPD | TRPV4 4626/4885ALDH1A1 2465/4885L3MBTL1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.